Designing representative clinical trials: Leverage real-world data for DE&I

Clinical trials play a pivotal role in progressing healthcare, yet the task of making clinical trials truly representative of diverse populations is an ongoing challenge. In our latest on-demand webinar, “Harnessing Real-World Data for DE&I: Keys to Designing Representative Clinical Trials,” we explore this critical issue, focusing on leveraging real-world data to enhance diversity in clinical trials.

Addressing the diversity challenge

Remarkably, 80% of health outcomes¹ are influenced by a patient’s social determinants of health (SDOH), including economic conditions, education, and the physical environment. Incorporating SDOH data into the design of clinical trials is essential for gaining a comprehensive understanding of diverse patient groups. This approach extends past the usual demographic information, providing a richer, more detailed perspective on the specific needs and reactions of different patient populations in different geographic regions.

The power of real-world data

Real-world data (RWD) is reshaping clinical research, and Inovalon’s primary source claims dataset, which is the industry’s largest, plays a significant role in this evolution. By utilizing RWD, we aim to facilitate more inclusive and effective clinical trials. Our approach combines advanced analytics with broad connectivity, offering valuable insights into diverse patient populations and contributing to more nuanced and representative research outcomes.

3 key factors for designing representative clinical trials:

• Measure Diversity: Analyze real-world patient populations and understand the impact of study designs on patient subgroup eligibility
• Model Impact: Understand the association of social determinants of health (SDOH) with outcomes and select diversity measures
• Mobilize Findings: Utilize insights to educate stakeholders, guide resource prioritization, and improve study diversity

Shaping an inclusive future

Recognizing and addressing SDOH factors earlier in development is crucial, as it leads to the pursuit of more equitable and effective healthcare solutions that are tailored to patients’ specific healthcare needs. Embracing these innovative strategies will not only align with regulatory guidance but also ensure that clinical trials are more representative, ethical, and effective.

Dive deeper into these insights by viewing our on-demand webinar. Together, let’s contribute to shaping a more equitable future in healthcare research.

View webinar

1. Robert Wood Johnson Foundation, Health Outcomes Framework

Inovalon and design^® and Inovalon^® are trademarks of Inovalon, Inc.